| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2022 | ALKS Alkermes Plc. | Jackson Blair Curtis | EVP, Chief Operating Officer | Sell | 49,999 | $29.61 | $1,480,335.39 | -36.3% | +1.1% | -1.5% | |
| Apr 20, 2022 | PCRX Pacira Biosciences, Inc. | Reinhardt Max79 | President, Rest Of World | Sell | 28,026 | $73.27 | $2,053,491.16 | -27.9% | -28.0% | -38.2% | |
| Apr 18, 2022 | LQDA Liquidia Corp | Manning Paul B54 | Director | Buy | 392,156 | $5.10 | $1,999,995.60 | New | -27.4% | +35.8% | |
| Apr 18, 2022 | BCRX Biocryst Pharmaceuticals Inc | Abercrombie George B68 | Director | Sell | 5,000 | $11.04 | $55,200.00 | -100% | +7.1% | -29.3% | |
| Apr 18, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 35,000 | $0.24 | $8,225.00 | -0.2% | - | - | |
| Apr 18, 2022 | LQDA Liquidia Corp | Caligan Partners LP58 | Director, 10% Owner, See Remarks | Buy | 1,764,705 | $5.10 | $8,999,995.50 | +21.2% | -27.4% | +35.8% | |
| Apr 18, 2022 | ALKS Alkermes Plc. | Cooke Shane62 | Director | Sell | 10,000 | $28.88 | $288,750.00 | -10.0% | +1.7% | +1.2% | |
| Apr 14, 2022 | BHC Bausch Health Companies Inc. | Spurr Robert82 | U.s. President-pharma Business | Sell | 1,595 | $22.19 | $35,393.05 | -1.7% | -59.4% | -66.2% | |
| Apr 14, 2022 | INM Inmed Pharmaceuticals Inc. | Adams Eric A | President &CEO | Buy | 14,160 | $0.89 | $12,659.04 | +31.6% | -50.9% | -94.3% | |
| Apr 13, 2022 | INM Inmed Pharmaceuticals Inc. | Adams Eric A | President &CEO | Buy | 8,560 | $0.85 | $7,276.00 | +23.6% | -47.8% | -94.4% | |
| Apr 13, 2022 | NIKA Nika Pharmaceuticals, Inc | Nika Pharmaceuticals, Inc | President, CEO, CFO | Buy | 11,489,000 | $0.01 | $137,868.00 | -100% | - | - | |
| Apr 13, 2022 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 41,389 | $6.75 | $279,502.30 | +0.6% | +3.8% | +226.4% | |
| Apr 11, 2022 | ASRT Assertio Holdings, Inc. | Peisert Daniel A.54 | President And CEO | Sell | 26,391 | $3.50 | $92,368.50 | -14.3% | +1.9% | +83.3% | |
| Apr 11, 2022 | ALKS Alkermes Plc. | Cooke Shane62 | Director | Sell | 10,000 | $29.26 | $292,601.00 | -10.0% | +7.7% | +0.5% | |
| Apr 8, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 139,045 | $310.79 | $43,213,795.43 | - | +5.6% | +18.9% | |
| Apr 7, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $185.52 | $1,113,094.53 | -5.0% | +27.2% | +19.5% | |
| Apr 7, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 70,955 | $309.82 | $21,982,985.06 | - | +7.4% | +20.5% | |
| Apr 6, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 51,851 | $300.92 | $15,603,020.67 | - | +7.3% | +21.6% | |
| Apr 6, 2022 | PCRX Pacira Biosciences, Inc. | Molloy Anthony74 | Chief Lgl &Compliance Officer | Sell | 22,500 | $76.42 | $1,719,392.73 | -26.8% | -26.1% | -46.9% | |
| Apr 5, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 113,756 | $293.86 | $33,428,338.93 | - | +12.2% | +25.0% | |
| Apr 5, 2022 | ASRT Assertio Holdings, Inc. | Peisert Daniel A.54 | President And CEO | Sell | 34,518 | $3.50 | $120,813.00 | -15.7% | +3.8% | +90.8% | |
| Apr 5, 2022 | PLSH Panacea Life Sciences Holdings, Inc. | Buttorff Leslie | CEO | Buy | 18,050 | $0.50 | $8,987.65 | +0.6% | - | - | |
| Apr 4, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 39,393 | $293.15 | $11,548,136.74 | - | +12.6% | +22.8% | |
| Apr 4, 2022 | ALKS Alkermes Plc. | Cooke Shane62 | Director | Sell | 10,000 | $28.18 | $281,845.00 | -10.0% | +9.5% | +1.4% | |
| Apr 4, 2022 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 12,655 | $57.38 | $726,143.90 | -13.1% | +14.1% | +45.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.